Lantheus Holdings (FRA:0L8) Current Accrued Expense : €115 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Current Accrued Expense?

Lantheus Holdings's Current Accrued Expense for the quarter that ended in Mar. 2024 was €115 Mil.

Lantheus Holdings's quarterly Current Accrued Expense increased from Sep. 2023 (€81 Mil) to Dec. 2023 (€86 Mil) and increased from Dec. 2023 (€86 Mil) to Mar. 2024 (€115 Mil).

Lantheus Holdings's annual Current Accrued Expense increased from Dec. 2021 (€27 Mil) to Dec. 2022 (€67 Mil) and increased from Dec. 2022 (€67 Mil) to Dec. 2023 (€86 Mil).

Lantheus Holdings Current Accrued Expense Historical Data

The historical data trend for Lantheus Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Current Accrued Expense Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

18.15

14.74

26.54

67.15

86.05

Lantheus Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															75.17	72.53	81.22	86.05	115.13

Lantheus Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Lantheus Holdings Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantheus Holdings (FRA:0L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

LNTH:USA 0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines